Asia Market Entry – Opportunities & Challenges
Anousha Kamvari, Ph.D.
A continent of extremes, with great potential for growth
Asia is a continent of diversity. Geographically large, the assortment of cultures, people, disease profiles, and healthcare systems added to the juxtaposition of extreme wealth and extreme poverty, emphasises the many challenges faced by the pharmaceutical companies when thinking of entering Asia. Countries such as Russia, India and China have traditionally been considered the key players in emerging markets.
However, vigorous economic growth, government healthcare reforms, population growth, increasing per capita income and changing disease profiles have led to a greater demand for healthcare and pharmaceuticals across other markets in the continent – nowhere more so than the 10 countries that comprise the Association of Southeast Asian Nations (ASEAN) – Indonesia, Malaysia, Philippines, Singapore, Thailand, Brunei, Myanmar, Cambodia, Laos, and Vietnam.
The ASEAN countries have a combined population of more than 625 million, nearly double that of the United States and more than 120 million higher than that of the EU. Topping $2.3 trillion, with a GDP per capita of US$3,748, their combined GDP is equal to around one-quarter that of China, and the region saw GDP growth of about 7% in 2013, compared with negative growth in the EU and approximately 2% growth in the United States1.
This opens a huge opportunity for pharmaceutical companies, amidst increasingly complex and evolving healthcare systems. Commercial success will depend on understanding the market dynamics by consolidating positioning within the market place with the requirements of each market.
About the author
Anousha Kamvari, PhD
Anousha is a Senior Consultant. Anousha offers broad experience across both the medical device and pharmaceutical industries. Her areas of expertise include strategic and operational leadership in market entry, market analytics, pricing and reimbursement, regulatory (FDA, EMA, CFDA) and compliance systems for medical devices including drug-device combination products and pharmaceuticals.
You may also be interested in…
How is COVID-19 impacting clinical trials?
As the impact of COVID-19 pandemic continues to expand globally, pharmaceutical and biotech players are beginning to feel the disruptive effects of the outbreak. New clinical trials will be significantly delayed as companies continue to face challenges arising from COVID-19, from potential patient quarantines, to site closures, travel limitations or interruptions to the supply chain for new investigational products.
Jennifer Cummins joins Deallus as Strategic Advisor
Deallus is excited to announce that Jenny Cummins will be partnering with Deallus as a Strategic Advisor. Jenny’s experience in formulating strategic direction within and outside of pharmaceutical companies is something we are excited to add to our panel of strategic advisors. Our clients will benefit from her expertise in the healthcare sector as well as her impressive leadership, communication, and facilitation skills.
Gloria Kwon Joins Deallus as Senior Principal
We are excited to announce that Gloria Kwon has joined our Deallus team as a Senior Principal based out of our Los Angeles office. Gloria comes to Deallus with significant experience in business strategy, product commercialization and operational excellence for pharmaceutical and biotechnology companies. Prior to joining Deallus, Gloria spent over 8 years at Navigant Consulting.
Peter Barschdorff joins Deallus as Vice President (U.S.)
Deallus is pleased to announce that Peter Barschdorff is joining the organization as Vice President, leading its U.S. consulting business, with offices in Los Angeles and New York. Peter has held leadership positions in a number of management consulting organizations and has built innovative enterprise capabilities in commercial pharma.
